Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADH300004 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ADH300004 | DRUG | - |
Inclusion Criteria: * Signed written informed consent * \> or = 19 years of age * Patients with histologically confirmed: * primary or metastatic (known or suspected) colorectal carcinoma requiring planned surgical resection with hepatic biopsy and systemic chemotherapy , or * primary or metas...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
ADH300004 is an investigational small molecule being studied for the treatment of neoplasms, specifically in patients with surgically resected primary or metastatic colorectal cancer. It is currently in Phase 1 clinical development and is not approved by the FDA.
ADH300004 is being developed by Fennec Pharmaceuticals Inc., a company traded on the stock exchange under the ticker symbol FENC. The drug is in Phase 1 clinical development for oncology indications.
ADH300004 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials.
ADH300004 has one completed Phase 1 clinical trial, identified as NCT00264446. This trial studied the drug in patients with surgically resected primary or metastatic colorectal cancer and liver biopsy, or planned hepatic resection, in the United States.
ADH300004 is the primary name for this investigational drug. No alternative names have been established for it in clinical development.